VANRAFIA™
(atrasentan) tablets
0.75 mg

ONBOARDING GUIDE

Getting started with VANRAFIA and available support for you and your patients

INDICATION

VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

IMPORTANT SAFETY INFORMATION

WARNING: EMBRYO-FETAL TOXICITY

VANRAFIA is contraindicated for use in pregnant patients; it may cause major birth defects, based on animal data. Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise use of effective contraception before the initiation of treatment, during treatment, and for 2 weeks after discontinuation of treatment with VANRAFIA. Stop VANRAFIA as soon as possible if the patient becomes pregnant.

Please click here for full Important Safety Information. Please click here for full Prescribing Information, including Boxed WARNING and Medication Guide.

Help your patients start their journey with VANRAFIA

PRESCRIPTION AND SUPPORT

Novartis Patient Support™ is a comprehensive program that can help your eligible patients start, stay, and save on treatment. Novartis Patient Support provides insurance, financial, and ongoing support for you and your patients.

Submit prescription

Submit Rx by downloading and completing a Start Form with Novartis Patient Support or at www.CoverMyMeds.health.

OR

Submit the Rx directly to CareMed* or Biologics by McKesson.

Download the Start Form at www.VANRAFIA-startform.com

*CareMed is a subsidiary of Onco360®.

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

Pregnancy

Use of VANRAFIA is contraindicated in patients who are pregnant.

Hypersensitivity

VANRAFIA is contraindicated in patients with a history of a hypersensitivity reaction to atrasentan or any component of the product.

Please click here for full Important Safety Information. Please click here for full Prescribing Information, including Boxed WARNING and Medication Guide.

VANRAFIA™ (atrasentan) tablets 0.75 mg

Choose one of two ways to prescribe VANRAFIA

Specialty pharmacy or Novartis Patient Support™

PRESCRIBE VANRAFIA THROUGH A SPECIALTY PHARMACY

SUBMIT Rx THROUGH ONE OF THE TWO SPECIALTY PHARMACIES

Biologics by McKesson
Website: biologics.mckesson.com
Phone: 1-800-850-4306 Fax: 1-800-823-4506

CareMed*
Website: caremedsp.com
Phone: 1-877-227-3405 Fax: 1-877-542-2731

Either of the two specialty pharmacies can help you access VANRAFIA. Ensure your patient is aware which specialty pharmacy will dispense their medication.

Novartis does not recommend or require the use of any particular pharmacy.

Inform your patient that the specialty pharmacy will reach out or call them directly and a confirmation of scheduling between patient and specialty pharmacy is required before VANRAFIA can be delivered.

The specialty pharmacy may be able to help you and your patients navigate the coverage process. Please reach out to the specialty pharmacy to learn more about the support that may be available.

SUPPORT TYPICALLY OFFERED BY SPECIALTY PHARMACIES CAN INCLUDE THE FOLLOWING:

ASSISTANCE NAVIGATING INSURANCE COVERAGE
- Benefits investigation and verification
- Prior authorization and appeals support

AFFORDABILITY AND SUPPORT
- Identification of financial support

ONGOING COMMUNICATION
- Refill outreach and shipment coordination
- Outbound patient continuity of care calls

Visit Biologics by McKesson

Visit CareMed*

*CareMed is a subsidiary of Onco360®.

Please click here for full Important Safety Information. Please click here for full Prescribing Information, including Boxed WARNING and Medication Guide.

VANRAFIA™ (atrasentan) tablets 0.75 mg

Choose one of two ways to prescribe VANRAFIA

Specialty pharmacy or **Novartis Patient Support**™

PRESCRIBE VANRAFIA THROUGH NOVARTIS PATIENT SUPPORT

SUBMIT Rx THROUGH NOVARTIS PATIENT SUPPORT

Submit the **Start Form** to **Novartis Patient Support** by downloading and faxing to 1-877-6VANRAF (1-877-682-6723) or electronically via the CoverMyMeds portal at **www.CoverMyMeds.health**.

Start Form: www.VANRAFIA-startform.com

Phone: 1-844-4VANRAF (1-844-482-6723) Monday through Friday, 8:00 AM to 8:00 PM ET, excluding holidays

Novartis Patient Support is a comprehensive program designed to help your patients start, stay, and save on their treatment. Learn more about Novartis Patient Support at 1-844-4VANRAF (1-844-482-6723) or www.VANRAFIA.com.

INSURANCE SUPPORT

Help navigating the insurance process, including benefits verification and support with prior authorization and appeals processes.

FINANCIAL SUPPORT

Assist with connecting patients to relevant saving options. Inform your eligible patients about the Co-Pay Plus offer.* Privately insured patients may pay as little as $0 for VANRAFIA.

ONGOING SUPPORT

Dedicated assistance from our team and educational resources to help your patients get started on treatment and guide them along the way.

Get your patients started
at www.VANRAFIA-startform.com

Eligible privately insured patients can receive up to 12 months of VANRAFIA (atrasentan) for free while coverage is pursued*

***Limitations apply.** Up to a $15,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with private insurance and a prior authorization requirement or an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at www.VANRAFIA.com for details.

Please click here for full Important Safety Information. Please click here for full Prescribing Information, including Boxed WARNING and Medication Guide.

VANRAFIA™ (atrasentan) tablets 0.75 mg

Additional support from Novartis

Novartis Patient Assistance Foundation

Novartis Patient Assistance Foundation, Inc. (NPAF), an independent 501(c)(3) non-profit organization, provides Novartis medicines free of cost to eligible patients who have limited or no prescription insurance coverage and cannot afford the cost of their medication.

Visit PAP.Novartis.com or call NPAF at 1-800-277-2254 to learn more about eligibility and how to apply.

QUESTIONS?

Call **Novartis Patient Support** at **1-844-4VANRAF (1-844-482-6723)**, Monday through Friday, 8:00 AM to 8:00 PM ET.

Please click here for full Important Safety Information. Please click here for full Prescribing Information, including Boxed WARNING and Medication Guide.

VANRAFIA™ (atrasentan) tablets 0.75 mg

Indication and Important Safety Information

INDICATION

VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

IMPORTANT SAFETY INFORMATION

WARNING: EMBRYO-FETAL TOXICITY

VANRAFIA is contraindicated for use in pregnant patients; it may cause major birth defects, based on animal data. Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise use of effective contraception before the initiation of treatment, during treatment, and for 2 weeks after discontinuation of treatment with VANRAFIA. Stop VANRAFIA as soon as possible if the patient becomes pregnant.

CONTRAINDICATIONS

Pregnancy

Use of VANRAFIA is contraindicated in patients who are pregnant.

Hypersensitivity

VANRAFIA is contraindicated in patients with a history of a hypersensitivity reaction to atrasentan or any component of the product.

WARNINGS AND PRECAUTIONS

Embryo-Fetal Toxicity

Based on data from animal reproduction studies, VANRAFIA may cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy. The available human data for endothelin receptor antagonists (ERAs) do not establish the presence or absence of major birth defects related to the use of VANRAFIA. Counsel patients who can become pregnant of the potential risk to a fetus. Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise patients to use effective contraception prior to initiation of treatment, during treatment, and for 2 weeks after discontinuation of treatment with VANRAFIA. When pregnancy is detected, discontinue VANRAFIA as soon as possible.

Additional Important Safety Information

Please click here for full Prescribing Information, including Boxed WARNING and Medication Guide.

VANRAFIA™ (atrasentan) tablets 0.75 mg

Important Safety Information (continued)

WARNINGS AND PRECAUTIONS (continued)

Hepatotoxicity

Some ERAs have caused elevations of aminotransferases, hepatotoxicity, and liver failure. Asymptomatic and transient transaminase elevations have been observed with VANRAFIA. Obtain liver enzyme testing before initiating VANRAFIA, and repeat during treatment as clinically indicated. In patients with elevated aminotransferases at baseline (>3 × upper limit of normal [ULN]), consider periodic liver test monitoring. Do not initiate VANRAFIA in patients with severe hepatic impairment.

Advise patients to report symptoms suggesting hepatic injury (eg, nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching). If clinically relevant aminotransferase elevations occur, or if elevations are accompanied by an increase in bilirubin >2 × ULN, or by clinical symptoms of hepatotoxicity, discontinue VANRAFIA. Consider reinitiation of VANRAFIA when hepatic enzyme levels normalize in patients who have not experienced clinical symptoms of hepatotoxicity or jaundice.

Fluid Retention

Fluid retention may occur with ERAs and has been observed in clinical studies with VANRAFIA. VANRAFIA has not been evaluated in IgAN patients with heart failure. If clinically significant fluid retention develops, consider initiating or increasing diuretic treatment and interrupting VANRAFIA treatment.

Decreased Sperm Counts

VANRAFIA, similar to other ERAs, may have an adverse effect on spermatogenesis. Counsel men about the potential effects on fertility.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5%) with VANRAFIA were peripheral edema and anemia.

EFFECT OF OTHER DRUGS ON VANRAFIA

Strong or Moderate CYP3A Inducers: Avoid concomitant use with a strong or moderate CYP3A inducer. Atrasentan is a CYP3A substrate. Concomitant use with a strong and moderate CYP3A inducer is expected to decrease atrasentan exposure, which may reduce VANRAFIA efficacy.

OATP1B1/1B3 Inhibitors: Avoid concomitant use with organic anion transporting polypeptides (OATP) 1B1/1B3 (OATP1B1/1B3) inhibitors. Atrasentan is an OATP1B1/1B3 substrate. Concomitant use with an OATP1B1/1B3 inhibitor increases atrasentan exposure, which may increase the risk of VANRAFIA adverse reactions.

Please click here for full Prescribing Information, including Boxed WARNING and Medication Guide.

VANRAFIA™ (atrasentan) tablets 0.75 mg

VANRAFIA™
(atrasentan) tablets
0.75 mg

Consider solidifying your foundation with a single addition to RASi ± SGLT2i for appropriate patients[1]

ADD ON VANRAFIA

Download the Start Form
Visit www.VANRAFIA-startform.com

Learn more about VANRAFIA
Visit www.VANRAFIA-HCP.com

RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor.

INDICATION

VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

IMPORTANT SAFETY INFORMATION

WARNING: EMBRYO-FETAL TOXICITY

VANRAFIA is contraindicated for use in pregnant patients; it may cause major birth defects, based on animal data. Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise use of effective contraception before the initiation of treatment, during treatment, and for 2 weeks after discontinuation of treatment with VANRAFIA. Stop VANRAFIA as soon as possible if the patient becomes pregnant.

Reference: 1. Vanrafia. Prescribing information. Novartis Pharmaceuticals Corp.

Please click here for full Important Safety Information. Please click here for full Prescribing Information, including Boxed WARNING and Medication Guide.

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

5/25

452203